Search Result

Results for "

molecular degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Molecular Glues (18) Apoptosis (15) Biochemical Assay Reagents (1) Btk (2) Casein Kinase (1) CDK (5) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) Epigenetic Reader Domain (2) FGFR (1) FKBP (1) HSP (1) HSV (1) Insulin Receptor (1) Isotope-Labeled Compounds (3) Ligands for E3 Ligase (10) LRRK2 (1) MDM-2/p53 (1) NF-κB (1) Phosphodiesterase (PDE) (1) PROTACs (5) Reactive Oxygen Species (1) SF3B1 (1) VEGFR (1)
By Research Areas:	Cancer (31) Infection (1) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Molecular Glues (18)

Apoptosis (15)

Biochemical Assay Reagents (1)

Btk (2)

Casein Kinase (1)

CDK (5)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (2)

FGFR (1)

FKBP (1)

HSP (1)

HSV (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (3)

Ligands for E3 Ligase (10)

LRRK2 (1)

MDM-2/p53 (1)

NF-κB (1)

Phosphodiesterase (PDE) (1)

PROTACs (5)

Reactive Oxygen Species (1)

SF3B1 (1)

VEGFR (1)

By Research Areas:

Cancer (31)

Infection (1)

Inflammation/Immunology (7)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Molecular Glues

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129917

KB02-JQ1 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 .

HY-129610

KB02-SLF	PROTACs FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .

HY-144981

HQ461	CDK Molecular Glues	Cancer
HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death .

HY-130122

MG-277	Molecular Glues PROTACs Apoptosis	Cancer
MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor based on Cereblon E3 ligand, GSPT1, with a DC₅₀ of 1.3 nM. MG-277 potently inhibits tumor cell growth in a p53-independent manner, with IC₅₀s of 3.5 nM for RS4;11 cells and 3.4 nM for p53 mutant RS4;11/IRMI-2 cells, respectively. Anticancer activity .

HY-160525

CDO1 degrader-1

Molecular Glues Cancer

CDO1 degrader-1 (compound 8) is a molecular glue degrader that targets cysteine dioxygenase (CDO1) .
HY-153385

TMX1

Epigenetic Reader Domain Apoptosis Cancer

TMX1 is a BRD4 covalent molecular glue degrader. TMX1 selectively recruits DCAF16 to BRD4BD2, resulting in the degradation of BRD4 .

CDO1 degrader-1	Molecular Glues	Cancer
CDO1 degrader-1 (compound 8) is a molecular glue degrader that targets cysteine dioxygenase (CDO1) .

TMX1	Epigenetic Reader Domain Apoptosis	Cancer
TMX1 is a BRD4 covalent molecular glue degrader. TMX1 selectively recruits DCAF16 to BRD4BD2, resulting in the degradation of BRD4 .

HY-148523

HQ005	Others	Cancer
HQ005 is a potent CCNK degrader with an DC₅₀ value of 0.041 µM. HQ005 is a molecular-glue degrader that mediates interactions between target proteins and components of the ubiquitin-proteasome system to cause selective protein degradation .

HY-W584512

Thalidomide-NH-CH2-COO(t-Bu)

Others Others

Thalidomide-NH-CH2-COO (t-Bu) is a molecular block of small-molecule degrader .
HY-141676

HyT36

Others Others

HyT36 is a low molecular weight hydrophobic tag that promotes the degradation of fusion protein and pseudokinase Her3 .
HY-163064

CC-3240

LRRK2 Cancer

CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC₅₀ of 9 nM .

Thalidomide-NH-CH2-COO(t-Bu)	Others	Others
Thalidomide-NH-CH2-COO (t-Bu) is a molecular block of small-molecule degrader .

HyT36	Others	Others
HyT36 is a low molecular weight hydrophobic tag that promotes the degradation of fusion protein and pseudokinase Her3 .

CC-3240	LRRK2	Cancer
CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC₅₀ of 9 nM .

HY-153803

GBD-9	PROTACs Molecular Glues Btk	Cancer
GBD-9 is a double-mechanism degrader that efficiently degrades BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1. GBD-9 effectively inhibits cancer cell growth .

HY-P2839

Heparinase Heparinase I	Endogenous Metabolite	Metabolic Disease
Heparinase (Heparinase I) degrades heparin to oligosaccharide or unsaturated disaccharide. Heparinase can be used in the preparation of low molecular weight heparin (LMWH) .

HY-160501

DS17

Molecular Glues CDK Cancer

DS17 is a molecular glue that acts as a potent degrader of cyclin K, with an EC₅₀ of 13 nM. DS17 plays an important role in cancer research .

DS17	Molecular Glues CDK	Cancer
DS17 is a molecular glue that acts as a potent degrader of cyclin K, with an EC₅₀ of 13 nM. DS17 plays an important role in cancer research .

HY-10984

Pomalidomide 10+ Cited Publications CC-4047	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-153220A

(R)-NX-2127	Btk	Inflammation/Immunology Cancer
(R)-NX-2127 (compound 28) is an orally active Bruton’s Tyrosine Kinase (Btk) degrader. (R)-NX-2127 degrades IKZF1 and IKZF3 by molecular glue interactions with the cereblon E3 ubiquitin ligase complex .

HY-156828

MMH2

Others Others

MMH2 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .
HY-156827

MMH1

Others Others

MMH1 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .

MMH2	Others	Others
MMH2 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .

MMH1	Others	Others
MMH1 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .

HY-10984S

Pomalidomide-d5 CC-4047-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-10984S2

Pomalidomide-d4 CC-4047-d₄	Isotope-Labeled Compounds Apoptosis Ligands for E3 Ligase Molecular Glues	Cancer
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

HY-10984S1

Pomalidomide-d3 CC-4047-d₃	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .

HY-130800

Eragidomide 1 Publications Verification CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation .

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Inflammation/Immunology Cancer
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease .

HY-122704A

Surfen dihydrochloride 1 Publications Verification Aminoquincarbamide dihydrochloride	FGFR HSV VEGFR	Infection
Surfen dihydrochloride is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection .

HY-131863

Pomalidomide 4'-alkylC8-acid	Ligands for E3 Ligase Apoptosis Molecular Glues	Cancer
Pomalidomide 4'-alkylC8-acid is an E3 ubiquitin ligase ligand-Linker conjugate containing Pomalidomide (HY-10984). Pomalidomide is a third-generation immunomodulator that acts like a molecular glue. Pomalidomide interacts with the E3 ligase cereblon to induce degradation of the essential Ikaros transcription factor .

HY-148776

PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)	Biochemical Assay Reagents	Others
PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .

HY-150641

CDK-IN-9	CDK Apoptosis DNA/RNA Synthesis	Cancer
CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC₅₀ values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II .

HY-49444

EN450	NF-κB E1/E2/E3 Enzyme	Cancer
EN450 is a cysteine-reactive covalent molecular glue degrader targeting NF-κB. EN450 interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D. EN450 induces the ternary complex formation between UBE2D and NFKB1. EN450 exerts its anti-proliferative effects through a Cullin E3 ligase and proteasome-dependent mechanism .

HY-115461

MID-1	Insulin Receptor	Metabolic Disease
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .

HY-A0003

Lenalidomide Maximum Cited Publications 32 Publications Verification CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-A0003B

Lenalidomide hemihydrate Maximum Cited Publications 32 Publications Verification CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Inflammation/Immunology Cancer
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-141881

PROTAC-O4I2	PROTACs Apoptosis SF3B1	Cancer
PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC₅₀ value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-N10502

Colletofragarone A2	MDM-2/p53 HSP	Cancer
Colletofragarone A2 can be be isolated from the fungus Colletotrichum sp. (13S020). Colletofragarone A2 inhibits mutant p53 and HSP90 with anti-cancer activity. Colletofragarone A2 promotes degradation and aggregation of mutant p53 and suppressing tumor growth in vivo .

HY-18340

(R)-CR8 CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8), a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-18340A

(R)-CR8 trihydrochloride CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

Molecular Glue Compound Library	35 Compounds compounds
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 35 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Heparinase Heparinase I	Biochemical Assay Reagents
Heparinase (Heparinase I) degrades heparin to oligosaccharide or unsaturated disaccharide. Heparinase can be used in the preparation of low molecular weight heparin (LMWH) .

Tyroserleutide hydrochloride	Peptides	Cancer
Tyroserleutide hydrochloride, isolated from the degradation products of porcine spleen , is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo .

Heparinase Heparinase I	Endogenous Metabolite	Metabolic Disease
Heparinase (Heparinase I) degrades heparin to oligosaccharide or unsaturated disaccharide. Heparinase can be used in the preparation of low molecular weight heparin (LMWH) .

Tyroserleutide	Peptides	Cancer
Tyroserleutide (YSL), isolated from the degradation products of porcine spleen , is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo .

Tyroserleutide TFA	Peptides	Cancer
Tyroserleutide TFA, isolated from the degradation products of porcine spleen , is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10502

Colletofragarone A2	Other Terpenoids Structural Classification Microorganisms Terpenoids	MDM-2/p53 HSP
Colletofragarone A2 can be be isolated from the fungus Colletotrichum sp. (13S020). Colletofragarone A2 inhibits mutant p53 and HSP90 with anti-cancer activity. Colletofragarone A2 promotes degradation and aggregation of mutant p53 and suppressing tumor growth in vivo .

Cat. No.	Product Name	Chemical Structure

HY-10984S1

Pomalidomide-d3
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-10984S

Pomalidomide-d5
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-10984S2

Pomalidomide-d4
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

molecular degrader

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products